Tag: semaglutide
Semaglutide reduces risk for major kidney disease events in patients with...
Findings from the FLOW trial, the first dedicated kidney outcomes trial with a glucagon-like peptide-1 (GLP-1) receptor agonist were reported at a symposium at...
Renal Interventions’ top 10 stories of May 2024
In May, we saw revolutionary new devices, trials that show promise for the future of chronic kidney disease (CKD), and the role of medication...
Renal Interventions 12
Highlights
New trial evidence regarding the use of semaglutide for patients with type 2 diabetes and chronic kidney disease from the 61st European Renal...
New data show semaglutide may protect kidney function in overweight patients
The SELECT (Semaglutide effects on heart disease and stroke in patients with overweight or obesity) trial has revealed the potential of semaglutide, a glucagon-like...
Semaglutide significantly reduces risk of major kidney disease events and mortality...
A study recently published in the New England Journal of Medicine (NEJM) has demonstrated that semaglutide (Novo Nordisk) significantly reduces the risk of major...
FLOW trial shows reduction in kidney disease progression in patients with...
Novo Nordisk has announced via press release the headline results from the kidney outcomes trial FLOW, coming after the decision to stop the trial...
New option for chronic kidney failure patients emerges as Ozempic trial...
Ozempic (Novo Nordisk) is a once-daily injection with US Food and Drug Administration (FDA) approval for use as a preventative treatment for strokes and...